were prospectively studied. The study endpoints included the incidence of SF, target-lesion revascularization (TLR) and stent thrombosis (ST) at oneyear follow-up. Clinical outcome after TLR was also followed-up.
RESULTS The SF rate was 12.5% (n¼426) from patient level and 16.9% (n¼991) from stent level, with a higher incidence in the stainless stent platform (23.0% vs. 12.0% with cobalt-chromium stent, p<0.001). No differences were noted between domestic and international DES. SF was correlated with clinical events. TLR was required in 88 (21%) patients with SF, with repeat new generation DES implantation in 80 patients and balloon angioplasty in eight patients. After 1523 (IQR) days follow-up, repeat ISR was detected in 19 (23.8%) patients, and six (7.5%) patients required repeat TLR. Of 19 repeat deployed DESs, SF occurred in three (1.6%) stents. By multivariate analysis, stents in RCA or LAD, longer stents, hinge motion, overlapping and stainless stent (including Cypher, Excel and Taxus stents) were the six independent predictors of SF.
CONCLUSION In an autopsy study, the incidence of SF was 29%, which is much higher than clinically reported (7). Obviously, asymptomatic SF, different definitions and modalities for SF, different percentages of surveillance angiography and longer follow-up duration contribute to the underestimation of SF in the real world (8). Theoretically, all pro-fracture factors facilitate the process of metal fatigue over time (9-12), a mechanism leading to the postulation that more frequent SF might be detected over one-year follow-up. Recently, Ohya et al. (13) reported that the incidence Type III and IV SF at oneyear after stenting using Cypher stent was 5.8%, similar to our results. However, we further found that clinically reported SF rate <2% over one-year among patients who had no SF confirmed by one-year angiography. On the other hand, SF does not happen equally among different stents, and we report more frequent SF in stainless steel stents. Our results demonstrated that SF at one-year after DES implantation was associated with higher rate of events, particularly in patients with graded SF (severe SF). SF rate after one-year follow-up was not common. Re-intervention using another DES resulted in a significant reduction of repeat TLR. BACKGROUND Percutaneous coronary intervention (PCI) to very small vessel disease remains controversial and challenging. The intended lesions usually are more diffuse, calcified and tortuous. Usage of thin strut bare metal stent (BMS) with excellent crossing profile in a very small vessel disease has increased the likelihood of procedural success.
METHODS Thin strut cobalt chromium BMS implantation in a priori pre-defined subgroups was investigated in a non-randomized, international, multi-center 'all-comers' observational study. Primary end-point was the 9-months clinically driven target lesion revascularization (TLR) rate and secondary end-points included the 9-months major adverse cardiac events (MACE) and procedural success rates. Data collection was done using an established electronic data acquisition form with built-in plausibility checks.
RESULTS A total of 783 patients with mean age of 70.4 AE 12.8 years were enrolled, 205 (26.2 %) of them have vessel diameters of 2.5 mm and smaller, and this group of patient was categorized as having very small vessel disease. Older age and diabetics are associated with higher incidence of very small vessels disease. Mean diameter for very small vessel was 2.05 AE 0.27 mm and mean diameter for vessel > 2.5 mm was 3.41 AE 0.55 mm. Pre-dilatation was performed more often in the very small vessel patients (52.2 % vs 42.2 %; p-value 0.007). There was no difference in overall technical success in a very small vessel disease (97.9 % vs 97.7 %). The 9-months TLR rate was 6.3 % for very small vessel and 3.7 % for vessel > 2.5 mm (p¼0.129). 9-months and in-hospital MACE between very small vessel and vessel > 2.5 mm were not significantly different either (13.1 % vs 9.2 %; p¼0.1265 and 5.2 % vs 3.7 %; p¼0.349) respectively.
CONCLUSION This study has demonstrated that the use of thin strut cobalt chromium BMS in very small vessel disease was safe and efficacious in the context of 'real-world' practice.
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Impact of Everolimus-Eluting Stent Length on Outcomes of Percutaneous Coronary Intervention
Hideki Yano 1 1 Nasu Red Cross Hospital, Japan BACKGROUND In previous trials, longer drug-eluting stent (DES) length has been associated with adverse clinical events. In current practice, the appearance of ultra long DES (33,38mm) led to cover the entire atherosclerotic lesion and the stented length tends to be longer than the lesion length. However, the impact on clinical outcomes of the ultra long everolimus-eluting stent (ULEES) implantation with diffuse long Coronary Lesions is not clearly investigated. The aim of this study was to investigate the impact of stent length on the relative safety and efficacy of everolimus-eluting stents (EES).
METHODS Consecutive 730 patients (801 lesions) treated with EES between April 2010 and January 2014 were divided into 4 groups according to stent length. The association between stented length and long-term outcomes was analyzed in ordinal categories (<15, 15 to 23, 24 to 32, and >32 mm) and as a continuous variable. Follow up period was 2-year and the restudy CAG was performed within 10-months after PCI. We compared the major adverse clinical events (MACE) between the two groups.
RESULTS
The prevalence of diabetes, chronic kidney disease, and the case of complex stent use were higher in the longest stented quartile than in the other three groups. Initial success rate was similar in four groups. There were no differences in 2-year TLR (1.9% vs.1.7% vs. 2.9% vs. 2.8%), stent thrombosis (0.6% vs 0% vs 1.0% vs 0.5%) and MACE (4.4% vs 3.3% vs 4.7% vs 4.7%) rates between 4 groups.
CONCLUSION Like a result of the use of spot EES with short lesion, our results suggest that the use of ultra long EES with diffuse long lesion is effective and safe. Contrary to expectation, ultra long stent with diffuse lesion wasn't the positive predictor of TLR. 
